Logo image of VRDN

VIRIDIAN THERAPEUTICS INC (VRDN) Stock Fundamental Analysis

USA - NASDAQ:VRDN - US92790C1045 - Common Stock

22.16 USD
+0.09 (+0.41%)
Last: 10/24/2025, 8:01:21 PM
22.6993 USD
+0.54 (+2.43%)
After Hours: 10/24/2025, 8:01:21 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to VRDN. VRDN was compared to 534 industry peers in the Biotechnology industry. The financial health of VRDN is average, but there are quite some concerns on its profitability. While showing a medium growth rate, VRDN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

VRDN had negative earnings in the past year.
In the past year VRDN has reported a negative cash flow from operations.
In the past 5 years VRDN always reported negative net income.
In the past 5 years VRDN always reported negative operating cash flow.
VRDN Yearly Net Income VS EBIT VS OCF VS FCFVRDN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

The Return On Assets of VRDN (-59.08%) is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -66.79%, VRDN is in line with its industry, outperforming 58.61% of the companies in the same industry.
Industry RankSector Rank
ROA -59.08%
ROE -66.79%
ROIC N/A
ROA(3y)-38.23%
ROA(5y)-47.6%
ROE(3y)-42.28%
ROE(5y)-52.28%
ROIC(3y)N/A
ROIC(5y)N/A
VRDN Yearly ROA, ROE, ROICVRDN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VRDN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VRDN Yearly Profit, Operating, Gross MarginsVRDN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K

More info and screens

6

2. Health

2.1 Basic Checks

VRDN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VRDN has more shares outstanding
The number of shares outstanding for VRDN has been increased compared to 5 years ago.
The debt/assets ratio for VRDN has been reduced compared to a year ago.
VRDN Yearly Shares OutstandingVRDN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
VRDN Yearly Total Debt VS Total AssetsVRDN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

An Altman-Z score of 12.24 indicates that VRDN is not in any danger for bankruptcy at the moment.
The Altman-Z score of VRDN (12.24) is better than 85.21% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that VRDN is not too dependend on debt financing.
VRDN has a Debt to Equity ratio of 0.02. This is comparable to the rest of the industry: VRDN outperforms 41.76% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 12.24
ROIC/WACCN/A
WACC9.37%
VRDN Yearly LT Debt VS Equity VS FCFVRDN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

VRDN has a Current Ratio of 11.01. This indicates that VRDN is financially healthy and has no problem in meeting its short term obligations.
VRDN has a better Current ratio (11.01) than 83.15% of its industry peers.
VRDN has a Quick Ratio of 11.01. This indicates that VRDN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 11.01, VRDN belongs to the top of the industry, outperforming 83.15% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 11.01
Quick Ratio 11.01
VRDN Yearly Current Assets VS Current LiabilitesVRDN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

VRDN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.41%.
Looking at the last year, VRDN shows a small growth in Revenue. The Revenue has grown by 6.64% in the last year.
Measured over the past years, VRDN shows a very negative growth in Revenue. The Revenue has been decreasing by -41.64% on average per year.
EPS 1Y (TTM)5.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.96%
Revenue 1Y (TTM)6.64%
Revenue growth 3Y-53.27%
Revenue growth 5Y-41.64%
Sales Q2Q%4.17%

3.2 Future

Based on estimates for the next years, VRDN will show a very strong growth in Earnings Per Share. The EPS will grow by 22.18% on average per year.
VRDN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 400.17% yearly.
EPS Next Y-8.74%
EPS Next 2Y-5.33%
EPS Next 3Y13.65%
EPS Next 5Y22.18%
Revenue Next Year-52.8%
Revenue Next 2Y1169.47%
Revenue Next 3Y864.85%
Revenue Next 5Y400.17%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VRDN Yearly Revenue VS EstimatesVRDN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
VRDN Yearly EPS VS EstimatesVRDN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -200 -400 -600

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VRDN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VRDN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VRDN Price Earnings VS Forward Price EarningsVRDN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VRDN Per share dataVRDN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

VRDN's earnings are expected to grow with 13.65% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.33%
EPS Next 3Y13.65%

More info and screens

0

5. Dividend

5.1 Amount

VRDN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIRIDIAN THERAPEUTICS INC

NASDAQ:VRDN (10/24/2025, 8:01:21 PM)

After market: 22.6993 +0.54 (+2.43%)

22.16

+0.09 (+0.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/bmo
Earnings (Next)11-10 2025-11-10/amc
Inst Owners117.55%
Inst Owner Change0.33%
Ins Owners0.04%
Ins Owner Change0%
Market Cap1.81B
Revenue(TTM)305.00K
Net Income(TTM)-344061000
Analysts85.22
Price Target37.88 (70.94%)
Short Float %13.57%
Short Ratio14.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.34%
Min EPS beat(2)2.88%
Max EPS beat(2)11.8%
EPS beat(4)3
Avg EPS beat(4)3.35%
Min EPS beat(4)-6.6%
Max EPS beat(4)11.8%
EPS beat(8)5
Avg EPS beat(8)1.79%
EPS beat(12)7
Avg EPS beat(12)-5.98%
EPS beat(16)9
Avg EPS beat(16)-6.46%
Revenue beat(2)2
Avg Revenue beat(2)34.57%
Min Revenue beat(2)0.65%
Max Revenue beat(2)68.49%
Revenue beat(4)4
Avg Revenue beat(4)53%
Min Revenue beat(4)0.65%
Max Revenue beat(4)84.21%
Revenue beat(8)4
Avg Revenue beat(8)12.64%
Revenue beat(12)5
Avg Revenue beat(12)18.46%
Revenue beat(16)6
Avg Revenue beat(16)7.49%
PT rev (1m)-3.86%
PT rev (3m)-5.69%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.53%
EPS NY rev (1m)-10.44%
EPS NY rev (3m)-6.8%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-7.72%
Revenue NY rev (1m)0.09%
Revenue NY rev (3m)-24.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5933.07
P/FCF N/A
P/OCF N/A
P/B 3.51
P/tB 3.51
EV/EBITDA N/A
EPS(TTM)-4.02
EYN/A
EPS(NY)-4.39
Fwd EYN/A
FCF(TTM)-3.79
FCFYN/A
OCF(TTM)-3.78
OCFYN/A
SpS0
BVpS6.31
TBVpS6.31
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -59.08%
ROE -66.79%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-38.23%
ROA(5y)-47.6%
ROE(3y)-42.28%
ROE(5y)-52.28%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 110.77%
Cap/Sales 175.41%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.01
Quick Ratio 11.01
Altman-Z 12.24
F-Score3
WACC9.37%
ROIC/WACCN/A
Cap/Depr(3y)191.45%
Cap/Depr(5y)174.87%
Cap/Sales(3y)166.8%
Cap/Sales(5y)103.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.96%
EPS Next Y-8.74%
EPS Next 2Y-5.33%
EPS Next 3Y13.65%
EPS Next 5Y22.18%
Revenue 1Y (TTM)6.64%
Revenue growth 3Y-53.27%
Revenue growth 5Y-41.64%
Sales Q2Q%4.17%
Revenue Next Year-52.8%
Revenue Next 2Y1169.47%
Revenue Next 3Y864.85%
Revenue Next 5Y400.17%
EBIT growth 1Y-48.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year8.33%
EBIT Next 3Y18.75%
EBIT Next 5Y36.92%
FCF growth 1Y-90.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-90.9%
OCF growth 3YN/A
OCF growth 5YN/A

VIRIDIAN THERAPEUTICS INC / VRDN FAQ

What is the fundamental rating for VRDN stock?

ChartMill assigns a fundamental rating of 3 / 10 to VRDN.


What is the valuation status for VRDN stock?

ChartMill assigns a valuation rating of 0 / 10 to VIRIDIAN THERAPEUTICS INC (VRDN). This can be considered as Overvalued.


How profitable is VIRIDIAN THERAPEUTICS INC (VRDN) stock?

VIRIDIAN THERAPEUTICS INC (VRDN) has a profitability rating of 1 / 10.


How financially healthy is VIRIDIAN THERAPEUTICS INC?

The financial health rating of VIRIDIAN THERAPEUTICS INC (VRDN) is 6 / 10.


Can you provide the expected EPS growth for VRDN stock?

The Earnings per Share (EPS) of VIRIDIAN THERAPEUTICS INC (VRDN) is expected to decline by -8.74% in the next year.